Sign In

Login

Password

Forgot Password ? Sign Up

ريفاستيجمين (Arabic Wikipedia)

Analysis of information sources in references of the Wikipedia article "ريفاستيجمين" in Arabic language version.

refsWebsite
Global rank Arabic rank
11web.archive.org
1st place
1st place
9doi.org
2nd place
5th place
9nih.gov
4th place
6th place
3wikidata.org
43rd place
2nd place
2archive.org
6th place
3rd place
2novartis.us
low place
low place
1worldcat.org
5th place
4th place
1ncats.io
low place
3,760th place
1yissum.co.il
low place
low place
1fda.gov
447th place
393rd place
1exelonpatch.com
low place
low place
1clinicaltherapeutics.com
low place
low place
1nejm.org
2,374th place
1,707th place

archive.org

clinicaltherapeutics.com

doi.org

  • Simon Maskell; Munir Pirmohamed (4 Mar 2022). "A reference set of clinically relevant adverse drug-drug interactions". Scientific Data (بالإنجليزية). 9 (1). DOI:10.1038/S41597-022-01159-Y. ISSN:2052-4463. QID:Q123478206.
  • Drug Indications Extracted from FAERS، DOI:10.5281/ZENODO.1435999، QID:Q56863002
  • Kumar، V. (2006). "Potential medicinal plants for CNS disorders: An overview". Phytotherapy Research. ج. 20 ع. 12: 1023–1035. DOI:10.1002/ptr.1970. PMID:16909441.
  • Gauthier، S.؛ Vellas، B.؛ Farlow، M.؛ Burn، D. (2006). "Aggressive course of disease in dementia". Alzheimer's & Dementia. ج. 2 ع. 3: 210. DOI:10.1016/j.jalz.2006.03.002.
  • Touchon، J.؛ Bergman، H.؛ Bullock، R.؛ Rapatz، G. N.؛ Nagel، J.؛ Lane، R. (2006). "Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology". Current Medical Research and Opinion. ج. 22 ع. 1: 49–59. DOI:10.1185/030079906X80279. PMID:16393430.
  • Burn، D.؛ Emre، M.؛ McKeith، I.؛ De Deyn، P. P.؛ Aarsland، D.؛ Hsu، C.؛ Lane، R. (2006). "Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease". Movement Disorders. ج. 21 ع. 11: 1899–1907. DOI:10.1002/mds.21077. PMID:16960863.
  • Cummings، J.؛ Lefevre، G.؛ Small، G.؛ Appel-Dingemanse، S. (2007). "Pharmacokinetic rationale for the rivastigmine patch". Neurology. ج. 69: S10. DOI:10.1212/01.wnl.0000281846.40390.50.
  • Jann، M. W.؛ Shirley، K. L.؛ Small، G. W. (2002). "Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors". Clinical Pharmacokinetics. ج. 41 ع. 10: 719–739. DOI:10.2165/00003088-200241100-00003. PMID:12162759.
  • Jann، M. W. (2000). "Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease". Pharmacotherapy. ج. 20 ع. 1: 1–12. DOI:10.1592/phco.20.1.1.34664. PMID:10641971.

exelonpatch.com

fda.gov

ncats.io

drugs.ncats.io

nejm.org

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

novartis.us

web.archive.org

wikidata.org

  • Simon Maskell; Munir Pirmohamed (4 Mar 2022). "A reference set of clinically relevant adverse drug-drug interactions". Scientific Data (بالإنجليزية). 9 (1). DOI:10.1038/S41597-022-01159-Y. ISSN:2052-4463. QID:Q123478206.
  • Drug Indications Extracted from FAERS، DOI:10.5281/ZENODO.1435999، QID:Q56863002
  • Inxight: Drugs Database، QID:Q57664317

worldcat.org

  • Simon Maskell; Munir Pirmohamed (4 Mar 2022). "A reference set of clinically relevant adverse drug-drug interactions". Scientific Data (بالإنجليزية). 9 (1). DOI:10.1038/S41597-022-01159-Y. ISSN:2052-4463. QID:Q123478206.

yissum.co.il

  • "Exelon". Yissum Technology Transfer. مؤرشف من الأصل في 2011-10-26. اطلع عليه بتاريخ 2010-10-07.